Search results
Results from the WOW.Com Content Network
According to the Journal Citation Reports, the journal has a 2022 impact factor of 3.4 and a 5-year impact factor of 3.8, ranking it 125th out of 278 journals in the category Pharmacology & Pharmacy. [1] It is in the first quartile of journals in the category "Medicine – Pharmacology (medical)" (51/255).
A sister journal, also published for the British Pharmacological Society by Wiley-Blackwell is the British Journal of Clinical Pharmacology. The journal publishes research papers, review articles, commentaries and correspondence in all fields of pharmacology. It also publishes themed issues, as well as supplements.
The Journal of Clinical Pharmacology is a peer-reviewed medical journal that covers the field of pharmacology. The editor-in-chief is Joseph S. Bertino, Jr. ( Bertino Consulting ). It was established in 1961 and is currently published by John Wiley & Sons in association with the American College of Clinical Pharmacology .
Clinical Pharmacology & Therapeutics is a monthly peer-reviewed medical journal which covers research on the nature, action, efficacy, and evaluation of therapeutics. The editor-in-chief is Piet van der Graaf . The journal was established in 1960 and is published by Wiley-Blackwell.
The journal obtained its current name in 1997. [2] The journal is published by John Wiley & Sons and the editor-in-chief is Leslie Citrome (New York Medical College). According to the Journal Citation Reports, the journal has a 2020 impact factor of 2.503, ranking it 73rd out of 169 journals in the category "Medicine, General & Internal". [3]
At least two people have died as severe storms and tornadoes tore through parts of Texas and Mississippi on Saturday, officials said, while a parade of atmospheric river-fueled storms batters the ...
According to the Journal Citation Reports, the journal received a 2014 impact factor of 2.966, ranking it 84th out of 254 journals in the category Pharmacology & Pharmacy. [ 1 ] References
From January 2008 to September 2008, if you bought shares in companies when Greg C. Smith joined the board, and sold them when he left, you would have a -81.4 percent return on your investment, compared to a -13.0 percent return from the S&P 500.